S&P 500   3,246.87 (-1.47%)
DOW   28,554.00 (-1.50%)
QQQ   218.15 (-2.04%)
AAPL   308.55 (-3.07%)
FB   214.61 (-1.53%)
MSFT   162.35 (-1.63%)
GOOGL   1,425.35 (-2.78%)
AMZN   1,831.16 (-1.64%)
CGC   22.25 (-1.77%)
BABA   204.80 (-4.19%)
MU   55.16 (-4.50%)
GE   11.52 (-1.71%)
TSLA   545.75 (-3.38%)
AMD   48.96 (-2.76%)
T   38.40 (-0.26%)
ACB   1.95 (-2.01%)
NFLX   342.64 (-2.98%)
BAC   32.87 (-2.00%)
DIS   136.02 (-2.90%)
GILD   63.34 (+0.30%)
S&P 500   3,246.87 (-1.47%)
DOW   28,554.00 (-1.50%)
QQQ   218.15 (-2.04%)
AAPL   308.55 (-3.07%)
FB   214.61 (-1.53%)
MSFT   162.35 (-1.63%)
GOOGL   1,425.35 (-2.78%)
AMZN   1,831.16 (-1.64%)
CGC   22.25 (-1.77%)
BABA   204.80 (-4.19%)
MU   55.16 (-4.50%)
GE   11.52 (-1.71%)
TSLA   545.75 (-3.38%)
AMD   48.96 (-2.76%)
T   38.40 (-0.26%)
ACB   1.95 (-2.01%)
NFLX   342.64 (-2.98%)
BAC   32.87 (-2.00%)
DIS   136.02 (-2.90%)
GILD   63.34 (+0.30%)
S&P 500   3,246.87 (-1.47%)
DOW   28,554.00 (-1.50%)
QQQ   218.15 (-2.04%)
AAPL   308.55 (-3.07%)
FB   214.61 (-1.53%)
MSFT   162.35 (-1.63%)
GOOGL   1,425.35 (-2.78%)
AMZN   1,831.16 (-1.64%)
CGC   22.25 (-1.77%)
BABA   204.80 (-4.19%)
MU   55.16 (-4.50%)
GE   11.52 (-1.71%)
TSLA   545.75 (-3.38%)
AMD   48.96 (-2.76%)
T   38.40 (-0.26%)
ACB   1.95 (-2.01%)
NFLX   342.64 (-2.98%)
BAC   32.87 (-2.00%)
DIS   136.02 (-2.90%)
GILD   63.34 (+0.30%)
S&P 500   3,246.87 (-1.47%)
DOW   28,554.00 (-1.50%)
QQQ   218.15 (-2.04%)
AAPL   308.55 (-3.07%)
FB   214.61 (-1.53%)
MSFT   162.35 (-1.63%)
GOOGL   1,425.35 (-2.78%)
AMZN   1,831.16 (-1.64%)
CGC   22.25 (-1.77%)
BABA   204.80 (-4.19%)
MU   55.16 (-4.50%)
GE   11.52 (-1.71%)
TSLA   545.75 (-3.38%)
AMD   48.96 (-2.76%)
T   38.40 (-0.26%)
ACB   1.95 (-2.01%)
NFLX   342.64 (-2.98%)
BAC   32.87 (-2.00%)
DIS   136.02 (-2.90%)
GILD   63.34 (+0.30%)
Log in

NYSE:AMRX - Amneal Pharmaceuticals Stock Price, Forecast & News

$4.67
-0.06 (-1.27 %)
(As of 01/27/2020 11:33 AM ET)
Today's Range
$4.53
Now: $4.67
$4.75
50-Day Range
$3.47
MA: $4.68
$5.55
52-Week Range
$2.27
Now: $4.67
$14.79
Volume349,981 shs
Average Volume1.49 million shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.61
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone908-947-3120

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.86 billion
Cash Flow$1.41 per share
Book Value$3.00 per share

Profitability

Net Income$-169,730,000.00

Miscellaneous

Employees6,000
Market Cap$1.40 billion
Next Earnings Date2/26/2020 (Confirmed)
OptionableOptionable

Receive AMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.


Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals Inc (NYSE:AMRX) released its earnings results on Wednesday, November, 6th. The company reported $0.04 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.13 by $0.09. The business earned $378.30 million during the quarter, compared to analysts' expectations of $403.90 million. Amneal Pharmaceuticals had a positive return on equity of 23.17% and a negative net margin of 19.61%. The company's revenue for the quarter was down 20.6% compared to the same quarter last year. During the same period last year, the business earned $0.28 earnings per share. View Amneal Pharmaceuticals' Earnings History.

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Amneal Pharmaceuticals.

How can I listen to Amneal Pharmaceuticals' earnings call?

Amneal Pharmaceuticals will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for AMRX?

12 brokerages have issued 12-month target prices for Amneal Pharmaceuticals' stock. Their forecasts range from $2.50 to $14.00. On average, they anticipate Amneal Pharmaceuticals' share price to reach $6.30 in the next year. This suggests a possible upside of 35.2% from the stock's current price. View Analyst Price Targets for Amneal Pharmaceuticals.

What is the consensus analysts' recommendation for Amneal Pharmaceuticals?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 2 sell ratings, 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amneal Pharmaceuticals.

What are Wall Street analysts saying about Amneal Pharmaceuticals stock?

Here are some recent quotes from research analysts about Amneal Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories Inc., is based in New Jersey, United States. " (1/7/2020)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month PT of $35 for AMRX shares post a 4Q18 beat and despite lower than anticipated guidance for 2019. We still believe that AMRX will be able to successfully grow from a mid-size generics company into a leading generics and specialty pharma company. Therefore, upward earnings revisions in 2020+ should drive the stock higher. These upward earnings revisions should come from: 1) new generic drug launches, 2) operating margin expansion, 3) high-margin brand drug sales, and 4) strategic M&A as well as tuck-in deals." (2/28/2019)

Has Amneal Pharmaceuticals been receiving favorable news coverage?

Media stories about AMRX stock have been trending somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amneal Pharmaceuticals earned a daily sentiment score of -1.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Amneal Pharmaceuticals.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a drop in short interest in January. As of January 15th, there was short interest totalling 4,960,000 shares, a drop of 13.9% from the December 31st total of 5,760,000 shares. Based on an average daily trading volume, of 2,870,000 shares, the short-interest ratio is currently 1.7 days. Currently, 6.0% of the shares of the company are sold short. View Amneal Pharmaceuticals' Current Options Chain.

Who are some of Amneal Pharmaceuticals' key competitors?

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Exelixis (EXEL), TherapeuticsMD (TXMD), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Nektar Therapeutics (NKTR), Canopy Growth (CGC), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Opko Health (OPK) and Progenics Pharmaceuticals (PGNX).

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the folowing people:
  • Mr. Paul M. Bisaro, Exec. Chairman (Age 58)
  • Mr. Chirag K. Patel, Co-Founder & Co-Chairman (Age 52)
  • Mr. Chintu Patel, Co-Founder & Co-Chairman (Age 47)
  • Mr. Robert A. Stewart, Pres, CEO & Director (Age 51)
  • Ms. Nikita Shah, Sr. VP & Chief HR Officer (Age 41)

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Strs Ohio (0.05%), FNY Investment Advisers LLC (0.02%), Assenagon Asset Management S.A. (0.01%) and NEXT Financial Group Inc (0.00%). Company insiders that own Amneal Pharmaceuticals stock include Andrew S Boyer, Bryan M Reasons, International Ltd Fosun, Joseph Todisco, Nikita Shah, Paul Bisaro, Peter R Terreri, Pradeep Bhadauria and Ted C Nark. View Institutional Ownership Trends for Amneal Pharmaceuticals.

Which institutional investors are selling Amneal Pharmaceuticals stock?

AMRX stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A. and Strs Ohio. View Insider Buying and Selling for Amneal Pharmaceuticals.

Which institutional investors are buying Amneal Pharmaceuticals stock?

AMRX stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC and NEXT Financial Group Inc. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Andrew S Boyer, International Ltd Fosun, Joseph Todisco, Paul Bisaro, Pradeep Bhadauria and Ted C Nark. View Insider Buying and Selling for Amneal Pharmaceuticals.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $4.66.

How big of a company is Amneal Pharmaceuticals?

Amneal Pharmaceuticals has a market capitalization of $1.39 billion and generates $1.86 billion in revenue each year. The company earns $-169,730,000.00 in net income (profit) each year or $0.95 on an earnings per share basis. Amneal Pharmaceuticals employs 6,000 workers across the globe.View Additional Information About Amneal Pharmaceuticals.

What is Amneal Pharmaceuticals' official website?

The official website for Amneal Pharmaceuticals is http://www.amneal.com/.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]


MarketBeat Community Rating for Amneal Pharmaceuticals (NYSE AMRX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  299 (Vote Outperform)
Underperform Votes:  365 (Vote Underperform)
Total Votes:  664
MarketBeat's community ratings are surveys of what our community members think about Amneal Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Featured Article: FinTech

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel